China’s up-and-coming pharma giants

Chinese pharmaceutical companies are advancing in early-stage research and clinical trials but remain about a decade behind global leaders like AstraZeneca. AstraZeneca's CFO, Aradhana Sarin, noted that Chinese firms lack the capability for global clinical trials but may challenge Western competitors within 10 years. The rise of GLP-1 drugs for weight loss could reshape pharmaceutical strategies and cancer prevalence patterns.